Multifunctional Liquid Crystal Nanoparticles for Cancer Therapy

Abhishesh   K.   Mehata; Deepa       Dehari; Amit       Gupta; Dangali    C.    Rabin; Alim       Miya

doi:10.2174/2405461506666210118114851

Abstract

Cancer is the second foremost reason for worldwide death, affecting every country of the globe. However, 70% of cancer-related death was reported from low- and middle-income nations. Delay in the detection and intervention of therapeutic agents in cancer patients also promoted a cancer-related mortality index. Currently, numerous nanomedicines are under development for advancing tumor diagnosis and therapeutic capability. Recently, liquid crystalline nanoparticles (LCNPs) have emerged as an attractive drug delivery system for both intravenous and non-intravenous applications. The widely explored LCNPs for cancer therapy include cubosomes and hexosomes. They have significant advantages over other drug delivery system, which includes, high internal surface area, unique solubilization properties and sustained release of entrapped drug molecules and co-loading of imaging and therapeutic agents in a single system. In this review, we have briefly discussed the advantages of LCNPs, preparation methods, and their multifunctional role in treating various cancers.

Keywords: Cancer, cubosomes, hexosomes, liquid crystalline nanoparticles, theranostics, therapy.

« Previous Next »

Graphical Abstract

[1] 
 WHO. CancerWorld Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer
[2] 
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin  2019; 69(1): 7-34.
[3] 
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin  2020; 70(1): 7-30.
[4] 
Stoyanoff TR, Rodríguez JP, Todaro JS, et al. Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins. Tumour Biol  2016; 37(10): 13581-93.
[5] 
Zanotelli MR, Reinhart-King CA. Mechanical forces in tumor angiogenesis. Adv Exp Med Biol  2018; 1092: 91-112.
[http://dx.doi.org/10.1007/978-3-319-95294-9_6] 
[6] 
Mehata AK, Dehari D. Bradford assay as a high-throughput bioanalytical screening method for conforming pathophysiological state of the animal. J Drug Deliv Ther  2020; 10(1-s): 105-10.
[http://dx.doi.org/10.22270/jddt.v10i1-s.3921] 
[7] 
Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res  1998; 58(7): 1408-16.
[PMID: 9537241] 
[8] 
Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med  2013; 19(11): 1423-37.
[http://dx.doi.org/10.1038/nm.3394] 
[9] 
Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med  2013; 19(11): 1450-64.
[http://dx.doi.org/10.1038/nm.3391] 
[10] 
Kato H, Nakajima M. Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg  2013; 61(6): 330-5.
[http://dx.doi.org/10.1007/s11748-013-0246-0] 
[11] 
Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience  2019; 13: 961.
[http://dx.doi.org/10.3332/ecancer.2019.961] 
[12] 
Galletti G, Leach BI, Lam L, Tagawa ST. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev  2017; 57: 16-27.
[http://dx.doi.org/10.1016/j.ctrv.2017.04.008] 
[13] 
Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull  2017; 7(3): 339-48.
[http://dx.doi.org/10.15171/apb.2017.041] 
[14] 
d’Amato TA, Landreneau RJ, Ricketts W, et al. Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg  2007; 133(2): 352-63.
[15] 
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer  2017; 17(1): 20-37.
[http://dx.doi.org/10.1038/nrc.2016.108] 
[16] 
Yue X, Dai Z. Liposomal nanotechnology for cancer theranostics. Curr Med Chem  2018; 25(12): 1397-408.
[http://dx.doi.org/10.2174/0929867324666170306105350] 
[17] 
Smith AM, Duan H, Mohs AM, Nie S. 
            Bioconjugated quantum dots for 
            in vivo
             molecular and cellular imaging.
           Adv Drug Deliv Rev  2008; 60(11): 1226-40.
[http://dx.doi.org/10.1016/j.addr.2008.03.015] 
[18] 
Srinivasan M, Rajabi M, Mousa SA. Multifunctional nanomaterials and their applications in drug delivery and cancer therapy. Nanomaterials (Basel)  2015; 5(4): 1690-703.
[http://dx.doi.org/10.3390/nano5041690] 
[19] 
Sajja HK, East MP, Mao H, Wang YA, Nie S, Yang L. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol  2009; 6(1): 43-51.
[http://dx.doi.org/10.2174/157016309787581066] 
[20] 
Wang MD, Shin DM, Simons JW, Nie S. Nanotechnology for targeted cancer therapy. Expert Rev Anticancer Ther  2007; 7(6): 833-7.
[http://dx.doi.org/10.1586/14737140.7.6.833] 
[21] 
Kamo T, Nakano M, Leesajakul W, Sugita A, Matsuoka H, Handa T. Nonlamellar liquid crystalline phases and their particle formation in the egg yolk phosphatidylcholine/diolein system. Langmuir  2003; 19(22): 9191-5.
[http://dx.doi.org/10.1021/la035313x] 
[22] 
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology  2018; 16(1): 71.
[23] 
Cervin C, Tinzl M, Johnsson M, Abrahamsson PA, Tiberg F, Dizeyi N. Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse model. Eur J Pharm Sci  2010; 41(2): 369-75.
[http://dx.doi.org/10.1016/j.ejps.2010.07.003] 
[24] 
Spillmann CM, Naciri J, Algar WR, Medintz IL, Delehanty JB. Multifunctional liquid crystal nanoparticles for intracellular fluorescent imaging and drug delivery. ACS Nano  2014; 8(7): 6986-97.
[http://dx.doi.org/10.1021/nn501816z] 
[25] 
Nag OK, Naciri J, Oh E, Spillmann CM, Delehanty JB. Targeted plasma membrane delivery of a hydrophobic cargo encapsulated in a liquid crystal nanoparticle carrier. J Vis Exp  2017; 120: e55181.
[26] 
Urandur S, Banala VT, Shukla RP, et al. Theranostic lyotropic liquid crystalline nanostructures for selective breast cancer imaging and therapy. Acta Biomater  2020; 113: 522-40.
[27] 
Hirlekar R, Jain S, Patel M, Garse H, Kadam V. Hexosomes: a novel drug delivery system. Curr Drug Deliv  2010; 7(1): 28-35.
[http://dx.doi.org/10.2174/156720110790396526] 
[28] 
Chaud MV, Rios AC, dos Santos CA, de Barros CT, de Souza JF, Alves TFR.  Nanostructure self-assembly for direct nose-to-brain drug delivery: a novel approach for cryptococcal meningitis. In: Rai M, Abd-Elsalam KA, eds.  Nanomycotoxicology. Cambridge, Massachusetts: Academic Press 2020; pp. 449-80.
[http://dx.doi.org/10.1016/B978-0-12-817998-7.00019-7] 
[29] 
Verma P, Ahuja M. Cubic liquid crystalline nanoparticles: optimization and evaluation for ocular delivery of tropicamide. Drug Deliv  2016; 23(8): 3043-54.
[http://dx.doi.org/10.3109/10717544.2016.1143057] 
[30] 
Li JC, Zhu N, Zhu JX, et al. Self-assembled cubic liquid crystalline nanoparticles for transdermal delivery of paeonol. Med Sci Monit  2015; 21: 3298-310.
[http://dx.doi.org/10.12659/MSM.894484] 
[31] 
Alcaraz N, Boyd BJ. Cubosomes as carriers for MRI contrast agents. Curr Med Chem  2017; 24(5): 470-82.
[http://dx.doi.org/10.2174/0929867323666160817141556] 
[32] 
Mo J, Milleret G, Nagaraj M. Liquid crystal nanoparticles for commercial drug delivery. Liq Cryst Rev  2017; 5(2): 69-85.
[http://dx.doi.org/10.1080/21680396.2017.1361874] 
[33] 
Fan Y, Chen H, Huang Z, et al. Taste- masking and colloidal-stable cubosomes loaded with Cefpodoxime proxetil for pediatric oral delivery. Int J Pharm  2020; 575: 118875.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118875] 
[34] 
Ding Y, Chow SH, Liu GS, et al. Annexin V-containing cubosomes for targeted early detection of apoptosis in degenerative retinal tissue. J Mater Chem B  2018; 6(46): 7652-61.
[35] 
Yasser M, Teaima M, El-Nabarawi M, El-Monem RA. 
            Cubosomal based oral tablet for controlled drug delivery of telmisartan: formulation, 
            in vitro
             evaluation and 
            in vivo
             comparative pharmacokinetic study in rabbits.
           Drug Dev Ind Pharm  2019; 45(6): 981-94.
[http://dx.doi.org/10.1080/03639045.2019.1590392.] 
[36] 
Lee DR, Park JS, Bae IH, Lee Y, Kim BM. Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution. Int J Nanomedicine  2016; 11: 853-71.
[37] 
Madheswaran T, Kandasamy M, Bose RJ, Karuppagounder V. Current potential and challenges in the advances of liquid crystalline nanoparticles as drug delivery systems. Drug Discov Today  2019; 24(7): 1405-12.
[http://dx.doi.org/10.1016/j.drudis.2019.05.004] 
[38] 
Yang D, Armitage B, Marder SR. Cubic liquid-crystalline nanoparticles. Angew Chem Int Ed Engl  2004; 43(34): 4402-9.
[39] 
Lakshmi NM, Yalavarthi PR, Vadlamudi HC, Thanniru J, Yaga GKH. Cubosomes as targeted drug delivery systems - a biopharmaceutical approach. Curr Drug Discov Technol  2014; 11(3): 181-8.
[40] 
Garg G, Saraf S, Saraf S. Cubosomes: an overview. Biol Pharm Bull  2007; 30(2): 350-3.
[http://dx.doi.org/10.1248/bpb.30.350] 
[41] 
Radiman S, Toprakcioglu C, McLeish T. Rheological study of ternary cubic phases. Langmuir  1994; 10(1): 61-7.
[http://dx.doi.org/10.1021/la00013a009] 
[42] 
von Eckardstein KL, Reszka R, Kiwit JC. Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma clinical observations. J Neurooncol  2005; 74(3): 305-9.
[43] 
Almgren M, Edwards K, Gustafsson J, Science I. Cryotransmission electron microscopy of thin vitrified samples. Curr Opin Colloid Interface Sci  1996; 1(2): 270-8.
[http://dx.doi.org/10.1016/S1359-0294(96)80015-X] 
[44] 
Spicer PT, Small WB, Lynch ML, Burns JL. Dry powder precursors of cubic liquid crystalline nanoparticles (cubosomes). J Nanopart Res  2002; 4(4): 297-311.
[http://dx.doi.org/10.1023/A:1021184216308] 
[45] 
Shanmugam T, Banerjee R. Nanostructured self assembled lipid materials for drug delivery and tissue engineering. Ther Deliv  2011; 2(11): 1485-516.
[http://dx.doi.org/10.4155/tde.11.105] 
[46] 
Han S, Shen JQ, Gan Y, et al. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin  2010; 31(8): 990-8.
[http://dx.doi.org/10.1038/aps.2010.98] 
[47] 
Sharma P, Dhawan S, Nanda S. Cubosome: a potential liquid crystalline carrier system. Curr Pharm Des  2020; 26(27): 3300-16.
[48] 
Ali MA, Kataoka N, Ranneh AH, et al. Enhancing the solubility and oral bioavailability of poorly water-soluble drugs using monoolein cubosomes. Chem Pharm Bull (Tokyo)  2017; 65(1): 42-8.
[http://dx.doi.org/10.1248/cpb.c16-00513] 
[49] 
Nithya R, Jerold P, Siram K. Cubosomes of dapsone enhanced permeation across the skin. J Drug Deliv Sci Technol  2018; 48: 75-81.
[http://dx.doi.org/10.1016/j.jddst.2018.09.002] 
[50] 
Sagalowicz L, Leser M, Watzke H, Michel M. Technology. Monoglyceride self-assembly structures as delivery vehicles. Trends Food Sci Technol  2006; 17(5): 204-14.
[http://dx.doi.org/10.1016/j.tifs.2005.12.012] 
[51] 
Gustafsson J, Ljusberg-Wahren H, Almgren M, Larsson K. Submicron particles of reversed lipid phases in water stabilized by a nonionic amphiphilic polymer. Langmuir  1997; 13(26): 6964-71.
[http://dx.doi.org/10.1021/la970566+] 
[52] 
Tran N, Bye N, Moffat BA, Wright DK, et al. 
            Dual-modality NIRF-MRI cubosomes and hexosomes: High throughput formulation and 
            in vivo
             biodistribution.
           Mater Sci Eng C Mater Biol Appl  2017; 71: 584-93.
[53] 
Jenni S, Picci G, Fornasier M, et al. Multifunctional cubic liquid crystalline nanoparticles for chemo- and photodynamic synergistic cancer therapy. Photochem Photobiol Sci  2020; 19(5): 674-80.
[54] 
Singhvi G, Banerjee S, Khosa A. Lyotropic liquid crystal nanoparticles: a novel improved lipidic drug delivery system. Organic materials as smart nanocarriers for drug delivery  2018; 417-517.
[http://dx.doi.org/10.1016/B978-0-12-813663-8.00011-7] 
[55] 
Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv  2009; 6(10): 1017-32.
[http://dx.doi.org/10.1517/17425240903167942] 
[56] 
Koo YE, Reddy GR, Bhojani M, et al. Brain cancer diagnosis and therapy with nanoplatforms. Adv Drug Deliv Rev  2006; 58(14): 1556-77.
[http://dx.doi.org/10.1016/j.addr.2006.09.012] 
[57] 
Mertins O, Mathews PD, Angelova A. Advances in the design of ph-sensitive cubosome liquid crystalline nanocarriers for drug delivery applications. Nanomaterials (Basel)  2020; 10(5): 963.
[http://dx.doi.org/10.3390/nano10050963] 
[58] 
Luo Q, Lin T, Zhang CY, et al. A novel glyceryl monoolein-bearing cubosomes for gambogenic acid: Preparation, cytotoxicity and intracellular uptake. Int J Pharm  2015; 493(1-2): 30-9.
[59] 
Nazaruk E, Majkowska-Pilip A, Bilewicz R. Lipidic cubic-phase nanoparticles-cubosomes for efficient drug delivery to cancer cells. ChemPlusChem  2017; 82(4): 570-5.
[http://dx.doi.org/10.1002/cplu.201600534] 
[60] 
Jiang WG, Sanders AJ, Katoh M, et al. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol  2015; 35: S244-75.
[61] 
Yamashita T, Kaneko S. Liver Cancer. Rinsho Byori  2016; 64(7): 787-96.
[PMID: 30695467] 
[62] 
Sia D, Villanueva A, Friedman SL, Lovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology  2017; 152(4): 745-61.
[63] 
Gravitz L. Liver cancer. Nature  2014; 516(7529): S1.
[64] 
Sethuraman V, Janakiraman K, Krishnaswami V, Natesan S, Kandasamy R. pH responsive delivery of lumefantrine with calcium phosphate nanoparticles loaded lipidic cubosomes for the site specific treatment of lung cancer. Chem Phys Lipids  2019; 224: 104763.
[65] 
 WHO; World Health Organization. Breast cancer. 2018. Available at: 
          https://www.who.int/cancer/prevention/diagnosis-screening/breast- cancer/en/
[66] 
DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin  2019; 69(6): 438-51.
[67] 
Qiao J, Dong P, Mu X, Qi L, Xiao R. 
            Folic acid-conjugated fluorescent polymer for up-regulation folate receptor expression study 
            via
             targeted imaging of tumor cells.
           Biosens Bioelectron  2016; 78: 147-53.
[http://dx.doi.org/10.1016/j.bios.2015.11.021] 
[68] 
Bwatanglang IB, Mohammad F, Yusof NA, et al. in vivo
             tumor targeting and anti-tumor effects of 5-fluororacil loaded, folic acid targeted quantum dot system.
           J Colloid Interface Sci  2016; 480: 146-58.
[69] 
Tian Y, Li JC, Zhu JX, et al. Folic acid-targeted etoposide cubosomes for theranostic application of cancer cell imaging and therapy. Med Sci Monit  2017; 23: 2426-35.
[http://dx.doi.org/10.12659/MSM.904683] 
[70] 
Rawla P. Epidemiology of Prostate Cancer. World J Oncol  2019; 10(2): 63-89.
[http://dx.doi.org/10.14740/wjon1191] 
[71] 
Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev  2014; 15(22): 9575-8.
[http://dx.doi.org/10.7314/APJCP.2014.15.22.9575] 
[72] 
Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol  2005; 23(32): 8247-52.
[73] 
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med  2004; 351(15): 1502-12.
[74] 
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med  2004; 351(15): 1513-20.
[75] 
Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med  2016; 67: 103-17.
[76] 
Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer  2020; 1873(1): 188314.
[http://dx.doi.org/10.1016/j.bbcan.2019.188314] 
[77] 
Murgia S, Falchi AM, Mano M, et al. Nanoparticles from lipid-based liquid crystals: emulsifier influence on morphology and cytotoxicity. J Phys Chem B  2010; 114(10): 3518-25.
[78] 
Zhang L, Li J, Tian D, Sun L, Wang X, Tian M. Theranostic combinatorial drug-loaded coated cubosomes for enhanced targeting and efficacy against cancer cells. Cell Death Dis  2020; 11(1): 1.
[http://dx.doi.org/10.1038/s41419-019-2182-0] 
[79] 
Caltagirone C, Falchi AM, Lampis S, et al. Cancer-cell-targeted theranostic cubosomes. Langmuir  2014; 30(21): 6228-36.
[http://dx.doi.org/10.1021/la501332u] [PMID: 24815031] 

Rights & Permissions Print Cite

Article Metrics

12

1

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/2405461506666210118114851	Print ISSN 2405-4615
Publisher Name Bentham Science Publisher	Online ISSN 2405-4623

Current Nanomaterials

Multifunctional Liquid Crystal Nanoparticles for Cancer Therapy

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Related Articles

Abstract